Eledon Pharmaceuticals, Inc. Common Stock ELDN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-06T20:57:05.169Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T20:57:00.095819696Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-06T20:57:04.677231+00:00
Eledon Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.40 | 171.6% | 72.0% | 1.81 | 430.7% | 44.9% |
| 25Δ | 4.18 | 162.7% | 64.2% | |||
| 30Δ | 3.95 | 153.8% | 56.4% | |||
| 35Δ | 3.73 | 144.9% | 48.6% | |||
| 40Δ | 3.51 | 136.0% | 40.8% | 2.59 | 180.4% | 15.1% |
| 45Δ | 3.29 | 127.2% | 33.0% | 2.86 | 189.7% | 13.7% |
| 50Δ | 3.06 | 118.3% | 25.2% | 3.13 | 198.9% | 12.4% |
| 55Δ | 2.84 | 109.4% | 17.4% | 3.40 | 208.1% | 11.0% |
| 60Δ | 2.62 | 100.5% | 9.6% | 3.68 | 217.3% | 9.7% |
| 65Δ | 2.46 | 96.1% | 5.2% | 3.95 | 226.6% | 8.3% |
| 70Δ | 2.38 | 96.6% | 4.4% | 4.22 | 235.8% | 7.0% |
| 75Δ | 2.30 | 97.0% | 3.6% | 4.49 | 245.0% | 5.6% |
| 80Δ | 2.21 | 97.5% | 2.8% | 4.76 | 254.3% | 4.3% |
20Δ
- Pseudo strike
- 4.40
- IV
- 171.6%
- B/E move
- 72.0%
- Pseudo strike
- 1.81
- IV
- 430.7%
- B/E move
- 44.9%
25Δ
- Pseudo strike
- 4.18
- IV
- 162.7%
- B/E move
- 64.2%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 3.95
- IV
- 153.8%
- B/E move
- 56.4%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 3.73
- IV
- 144.9%
- B/E move
- 48.6%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 3.51
- IV
- 136.0%
- B/E move
- 40.8%
- Pseudo strike
- 2.59
- IV
- 180.4%
- B/E move
- 15.1%
45Δ
- Pseudo strike
- 3.29
- IV
- 127.2%
- B/E move
- 33.0%
- Pseudo strike
- 2.86
- IV
- 189.7%
- B/E move
- 13.7%
50Δ
- Pseudo strike
- 3.06
- IV
- 118.3%
- B/E move
- 25.2%
- Pseudo strike
- 3.13
- IV
- 198.9%
- B/E move
- 12.4%
55Δ
- Pseudo strike
- 2.84
- IV
- 109.4%
- B/E move
- 17.4%
- Pseudo strike
- 3.40
- IV
- 208.1%
- B/E move
- 11.0%
60Δ
- Pseudo strike
- 2.62
- IV
- 100.5%
- B/E move
- 9.6%
- Pseudo strike
- 3.68
- IV
- 217.3%
- B/E move
- 9.7%
65Δ
- Pseudo strike
- 2.46
- IV
- 96.1%
- B/E move
- 5.2%
- Pseudo strike
- 3.95
- IV
- 226.6%
- B/E move
- 8.3%
70Δ
- Pseudo strike
- 2.38
- IV
- 96.6%
- B/E move
- 4.4%
- Pseudo strike
- 4.22
- IV
- 235.8%
- B/E move
- 7.0%
75Δ
- Pseudo strike
- 2.30
- IV
- 97.0%
- B/E move
- 3.6%
- Pseudo strike
- 4.49
- IV
- 245.0%
- B/E move
- 5.6%
80Δ
- Pseudo strike
- 2.21
- IV
- 97.5%
- B/E move
- 2.8%
- Pseudo strike
- 4.76
- IV
- 254.3%
- B/E move
- 4.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 105.57% | |
| 150.61% | |
| 193.14% | |
| 130.66% | |
| 118.12% | |
| 120.56% | |
| 113.59% | |
| 111.09% |
Biotechnology
ELTX
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002,…
More →ELVN
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its…
More →ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to…
More →ENTA
Description unavailable
More →ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical…
More →ERAS
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in…
More →